Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haifu Li

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: rationale and efficacyThomas Van Looy, Agnieszka Wozniak, Giuseppe Floris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 13, 2012
A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawalGiuseppe Floris, Agnieszka Wozniak, Raf Sciot, et al.
Translational Lung Cancer Research|January 20, 2025
Efficacy, safety, and quality of life of dabrafenib plus trametinib treatment in Chinese patients with <i>BRAF</i> <sup>V600E</sup> mutation-positive metastatic non-small cell lung cancerYun Fan, Jianying Zhou, Yuanyuan Zhao, et al.
European Journal of Cancer (Oxford, England : 1990)|June 14, 2020
Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanomaLu Si, Xiaoshi Zhang, Sang Joon Shin, et al.
Molecular Cancer Therapeutics|April 10, 2019
Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug TestingJasmien Cornillie, Agnieszka Wozniak, Haifu Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2011
Large-scale analysis of KIT aberrations in Chinese patients with melanomaYan Kong, Lu Si, Yanyan Zhu, et al.
Cancer Biotherapy & Radiopharmaceuticals|February 14, 2026
Pharmacokinetics and Dosimetry of [<sup>68</sup>Ga]Ga-PSMA-11 in Chinese Participants with Progressive Metastatic Castration-Resistant Prostate Cancer: A Phase 2 StudyWei Fan, Yonghong Li, Hongcheng Shi, et al.
EJNMMI Research|March 1, 2026
A phase II study evaluating pharmacokinetics and dosimetry of <sup>177</sup>Lu-PSMA-617 radioligand therapy in Chinese participants with progressive metastatic castration-resistant prostate cancerHongcheng Shi, Jianming Guo, Wei Fan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2011
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplificationJun Guo, Lu Si, Yan Kong, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: rationale and efficacyThomas Van Looy, Agnieszka Wozniak, Giuseppe Floris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 13, 2012
A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawalGiuseppe Floris, Agnieszka Wozniak, Raf Sciot, et al.
Translational Lung Cancer Research|January 20, 2025
Efficacy, safety, and quality of life of dabrafenib plus trametinib treatment in Chinese patients with <i>BRAF</i> <sup>V600E</sup> mutation-positive metastatic non-small cell lung cancerYun Fan, Jianying Zhou, Yuanyuan Zhao, et al.
European Journal of Cancer (Oxford, England : 1990)|June 14, 2020
Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanomaLu Si, Xiaoshi Zhang, Sang Joon Shin, et al.
Molecular Cancer Therapeutics|April 10, 2019
Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug TestingJasmien Cornillie, Agnieszka Wozniak, Haifu Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2011
Large-scale analysis of KIT aberrations in Chinese patients with melanomaYan Kong, Lu Si, Yanyan Zhu, et al.
Cancer Biotherapy & Radiopharmaceuticals|February 14, 2026
Pharmacokinetics and Dosimetry of [<sup>68</sup>Ga]Ga-PSMA-11 in Chinese Participants with Progressive Metastatic Castration-Resistant Prostate Cancer: A Phase 2 StudyWei Fan, Yonghong Li, Hongcheng Shi, et al.
EJNMMI Research|March 1, 2026
A phase II study evaluating pharmacokinetics and dosimetry of <sup>177</sup>Lu-PSMA-617 radioligand therapy in Chinese participants with progressive metastatic castration-resistant prostate cancerHongcheng Shi, Jianming Guo, Wei Fan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2011
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplificationJun Guo, Lu Si, Yan Kong, et al.
Pageof 3